As of Feb 27
| +0.03 / +0.16%|
The 7 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 26.00, with a high estimate of 38.00 and a low estimate of 21.50. The median estimate represents a +34.99% increase from the last price of 19.26.
The current consensus among 8 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.